Physician profile
Ryan Hebert
NPI 1366282857
$3,336.15
in general payments reported to CMS, 2019-2025
25 companies · $2,181 in 2025
The $2,181 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,156 · 2025: $2,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,741 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $380 · Travel and Lodging: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,740.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $380.00 |
| Travel and Lodging | $215.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $466.99 | 2024-2025 | Ingrezza |
| Pfizer INC. | $380.00 | 2024 | |
| Novo Nordisk INC | $276.66 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $276.15 | 2024-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $255.83 | 2024-2025 | Pifeltro, Delstrigo, Capvaxive |
| Gilead Sciences, INC. | $253.92 | 2024-2025 | Epclusa, Biktarvy |
| Asahi Intecc Co., Ltd. | $215.33 | 2024 | Peripheral Vascular |
| Janssen Pharmaceuticals, INC | $168.77 | 2025 | Spravato, Invega |
| Otsuka America Pharmaceutical, INC. | $147.36 | 2025 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $144.13 | 2025 | Aristada, Lybalvi, Vivitrol |
| Exact Sciences Corporation | $100.33 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $84.21 | 2025 | |
| Axsome Therapeutics, INC. | $78.97 | 2024-2025 | Auvelity, Symbravo |
| Corium, LLC | $74.46 | 2024-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $63.62 | 2024-2025 | Takhzyro, Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $61.22 | 2025 | Ruconest |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.18 | 2025 | Caplyta |
| Viiv Healthcare Company | $54.97 | 2025 | Apretude |
| Biocryst US Sales Co., LLC | $47.67 | 2025 | Orladeyo |
| Indivior INC. | $29.79 | 2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $27.32 | 2025 | Fanapt |
| Ardelyx, INC. | $19.18 | 2025 | Ibsrela |
| Lilly USA, LLC | $18.91 | 2025 | Mounjaro |
| Lundbeck LLC | $18.08 | 2025 | Abilify Asimtufii |
| Braeburn INC. | $16.10 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.